References

In vivo pharmacodynamic activity of daptomycin

10.1128/aac.48.1.63-68.2004 · 2004 · External reference

Unresolved reference

2022 · External reference

Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of Veterans Affairs patients

10.1093/cid/civ444 · 2015 · External reference

Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: an updated systematic review and meta-analysis

10.1016/j.jgar.2019.10.008 · 2020 · External reference

Mechanisms of drug resistance: daptomycin resistance

10.1111/nyas.12948 · 2015 · External reference

Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin

10.1093/jac/dkac164 · 2022 · External reference

Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia

10.1093/cid/cix024 · 2017 · External reference

Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among Veterans Affairs patients

10.1093/cid/ciw815 · 2017 · External reference

Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis

10.1177/1060028013503110 · 2013 · External reference

Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis

10.1128/aac.02000-12 · 2013 · External reference

Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease

10.1111/jcpt.13289 · 2021 · External reference

Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis

10.1002/phar.1413 · 2014 · External reference

Safety of daptomycin in patients receiving hemodialysis

10.1592/phco.31.7.665 · 2011 · External reference

Optimizing the dosing regimens of daptomycin based on the susceptible dose-dependent breakpoint against vancomycin-resistant enterococci infection

10.3390/antibiotics8040245 · 2019 · External reference

Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint

10.1093/cid/ciy749 · 2019 · External reference

Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review

10.1093/jac/dky072 · 2018 · External reference

Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations

10.1128/aac.06439-11 · 2012 · External reference

Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose

10.1016/j.cmi.2016.07.018 · 2016 · External reference

Association of Higher daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus bacteremia

10.1002/phar.2070 · 2018 · External reference

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis

10.1086/652767 · 2010 · External reference

Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients

10.1186/1471-2334-13-66 · 2013 · External reference

Identification of risk factors for daptomycin-associated creatine phosphokinase elevation and development of a risk prediction model for incidence probability

10.1093/ofid/ofab568 · 2021 · External reference

Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients

10.1093/ndt/gfp655 · 2010 · External reference

Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis

10.1128/aac.01224-10 · 2011 · External reference

Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis

10.2215/cjn.01650309 · 2009 · External reference

Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis

2011 · External reference

Pilot pharmacokinetic study of high-dose daptomycin in hemodialysis patients with infected medical devices

10.1053/j.ajkd.2017.05.011 · 2017 · External reference

Safety of high-dose daptomycin in patients with severe renal impairment

10.2147/tcrm.s159587 · 2018 · External reference